Nitisinone structure
|
Common Name | Nitisinone | ||
|---|---|---|---|---|
| CAS Number | 104206-65-7 | Molecular Weight | 329.228 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 486.2±45.0 °C at 760 mmHg | |
| Molecular Formula | C14H10F3NO5 | Melting Point | 129-131°C | |
| MSDS | Chinese USA | Flash Point | 247.9±28.7 °C | |
Use of NitisinoneNitisinone(SC0735) is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase.Target: 4-Hydroxyphenylpyruvate DioxygenaseNitisinone is a drug used to slow the effects of hereditary tyrosinemia type 1. Nitisinone reduced urinary HGA levels from an average of 4.0 +/- 1.8 (SD) g/day to 0.2 +/- 0.2 g/day ( P < .001). Low-dose nitisinone effectively reduced urinary HGA levels in patients with alkaptonuria. Future long-term clinical trials are planned to determine the benefits of nitisinone in preventing joint deterioration and providing pain relief, and its long-term side effects [1]. Nitisinone can prevent the development of liver disease and significantly reduce the risk of developing hepatocellular carcinoma; however, vigorous surveillance for the development of HCC needs to be continued lifelong [2]. |
| Name | nitisinone |
|---|---|
| Synonym | More Synonyms |
| Description | Nitisinone(SC0735) is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase.Target: 4-Hydroxyphenylpyruvate DioxygenaseNitisinone is a drug used to slow the effects of hereditary tyrosinemia type 1. Nitisinone reduced urinary HGA levels from an average of 4.0 +/- 1.8 (SD) g/day to 0.2 +/- 0.2 g/day ( P < .001). Low-dose nitisinone effectively reduced urinary HGA levels in patients with alkaptonuria. Future long-term clinical trials are planned to determine the benefits of nitisinone in preventing joint deterioration and providing pain relief, and its long-term side effects [1]. Nitisinone can prevent the development of liver disease and significantly reduce the risk of developing hepatocellular carcinoma; however, vigorous surveillance for the development of HCC needs to be continued lifelong [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 486.2±45.0 °C at 760 mmHg |
| Melting Point | 129-131°C |
| Molecular Formula | C14H10F3NO5 |
| Molecular Weight | 329.228 |
| Flash Point | 247.9±28.7 °C |
| Exact Mass | 329.051117 |
| PSA | 97.03000 |
| LogP | 1.37 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.535 |
| InChIKey | OUBCNLGXQFSTLU-UHFFFAOYSA-N |
| SMILES | O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-] |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Hazard Codes | Xi |
|---|---|
| RIDADR | NONH for all modes of transport |
| HS Code | 2914700090 |
| HS Code | 2914700090 |
|---|---|
| Summary | HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0% |
|
Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
PLoS Biol. 9(7) , e1001099, (2011) Using the murine model of tyrosinemia type 1 (fumarylacetoacetate hydrolase [FAH] deficiency; FAH⁻/⁻ mice) as a paradigm for orphan disorders, such as hereditary metabolic liver diseases, we evaluated... |
|
|
Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
Ann. Clin. Biochem. 52 , 597-605, (2015) Alkaptonuria is a rare debilitating autosomal recessive disorder of tyrosine metabolism, where deficiency of homogentisate 1,2-dioxygenase results in increased homogentisic acid. Homogentisic acid is ... |
|
|
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)
|
| nitisinonum |
| 2-(2-Nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione |
| 2-[2-Nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione |
| 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione |
| Orfadin |
| Nitisinone [INN] |
| nitisinona |
| Orfadin (TN) |
| 1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- |
| Nitisone |
| 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione |
| 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione |
| Nitisinone |